source
- Atara and Pierre Fabre resubmit Ebvallo cell therapy after second FDA rejectionAtara Biotherapeutics and Pierre Fabre Pharmaceuticals have filed a new FDA submission for their cell therapy candidate Ebvallo (tabelecleucel), aimed at treating Epstein‑Barr virus‑positive post‑t…
- Poll finds most rural MAHA supporters say Trump health policies have not improved community healthA new Associated Press‑KFF poll of more than 2,000 rural registered voters shows that while about half of respondents identify with the Make America Healthy Again (MAHA) movement, roughly eight in…